Iwata, Takashi

写真a

Affiliation

School of Medicine, Department of Obstetrics and Gynecology (Gynecology) （Shinanomachi）

Position

Assistant Professor/Senior Assistant Professor
Page Top ▲

Academic Background 【 Display / hide 】

  • 1995

    慶応義塾大学, 医学部, 医学科

    Graduated

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 日本婦人科腫瘍学会婦人科腫瘍専門医

  • 日本臨床細胞学会細胞診専門医

  • 日本がん治療認定医機構がん治療認定医

  • 日本がん治療認定医機構暫定教育医

  • 日本産科婦人科学会専門医

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Obstetrics and gynecology

Page Top ▲

Research Keywords 【 Display / hide 】

  • 婦人科腫瘍の免疫学的特性

  • 子宮頸癌の臨床病理的特徴

  • 子宮頸部での局所免疫応答

Page Top ▲
 

Books 【 Display / hide 】

  • 子宮頚癌治療ガイドライン　２０１７年度版

    Iwata Takashi, 金原出版株式会社, 2017.07

Page Top ▲

Papers 【 Display / hide 】

  • Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions.

    Nishio H, Matsuda R, Iwata T, Yamagami W

    Japanese journal of clinical oncology  2024.02

    ISSN  0368-2811

  • Proposal for the optimal staging of extramammary Paget's disease: A retrospective analysis of 57 cases with distant metastasis.

    Funakoshi T, Nakamura Y, Hirai I, Kobayashi K, Fukuda K, Iwata T

    Experimental dermatology 33 （ 2 ） e15017 2024.02

    ISSN  0906-6705

  • SCD1 inhibition enhances the effector functions of CD8<sup>+</sup> T cells via ACAT1-dependent reduction of esterified cholesterol

    Sugi T., Katoh Y., Ikeda T., Seta D., Iwata T., Nishio H., Sugawara M., Kato D., Katoh K., Kawana K., Yaguchi T., Kawakami Y., Hirai S.

    Cancer Science （Cancer Science)  115 （ 1 ） 48 - 58 2024.01

    ISSN  13479032

    　View Summary

    We previously reported that the inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor function of CD8+ T cells indirectly via restoring production of DC recruiting chemokines by cancer cells and subsequent induction of antitumor CD8+ T cells. In this study, we investigated the molecular mechanism of direct enhancing effects of SCD1 inhibitors on CD8+ T cells. In vitro treatment of CD8+ T cells with SCD1 inhibitors enhanced IFN-γ production and cytotoxic activity of T cells along with decreased oleic acid and esterified cholesterol, which is generated by cholesterol esterase, acetyl-CoA acetyltransferase 1 (ACAT1), in CD8+ T cells. The addition of oleic acid or cholesteryl oleate reversed the enhanced functions of CD8+ T cells treated with SCD1 inhibitors. Systemic administration of SCD1 inhibitor to MCA205 tumor-bearing mice enhanced IFN-γ production of tumor-infiltrating CD8+ T cells, in which oleic acid and esterified cholesterol, but not cholesterol, were decreased. These results indicated that SCD1 suppressed effector functions of CD8+ T cells through the increased esterified cholesterol in an ACAT1-dependent manner, and SCD1 inhibition enhanced T cell activity directly through decreased esterified cholesterol. Finally, SCD1 inhibitors or ACAT1 inhibitors synergistically enhanced the antitumor effects of anti-PD-1 antibody therapy or CAR-T cell therapy in mouse tumor models. Therefore, the SCD1–ACAT1 axis is regulating effector functions of CD8+ T cells, and SCD1 inhibitors, and ACAT1 inhibitors are attractive drugs for cancer immunotherapy.

  • Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3.

    Kawana K, Kobayashi O, Ikeda Y, Yahata H, Iwata T, Satoh T, Akiyama A, Maeda D, Hori-Hirose Y, Uemura Y, Nakayama-Hosoya K, Katoh K, Katoh Y, Nakajima T, Taguchi A, Komatsu A, Asai-Sato M, Tomita N, Kato K, Aoki D, Igimi S, Kawana-Tachikawa A, Schust DJ.

    JNCI Cancer Spectr 7 （ 6 ）  2023.11

    Accepted

  • Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer

    Kitazawa S., Chiyoda T., Nakamura K., Sakai K., Yoshihama T., Nishio H., Kobayashi Y., Iwata T., Banno K., Yamagami W., Nishihara H., Aoki D.

    International Journal of Clinical Oncology （International Journal of Clinical Oncology)  28 （ 11 ） 1554 - 1562 2023.11

    ISSN  13419625

    　View Summary

    Background: Japan’s health insurance covers multigene panel testing. This study aimed to determine the potential availability and utility of gene panel testing clinically in gynecologic oncology. Methods: We analyzed the characteristics of patients with gynecologic cancer who underwent gene panel testing using FoundationOne® CDx or OncoGuide™ NCC Oncopanel between November 2019 and October 2022. Results: Out of 102 patients analyzed, 32, 18, 43, 8, and 1 had cervical, endometrial, ovarian cancers, sarcoma, and vaginal cancer, respectively. Druggable gene alteration was found in 70 patients (68.6%; 21 with cervical cancer, 15 with endometrial cancer, 28 with ovarian cancer, 5 with sarcoma, and 1 with other). The most common druggable gene alteration was PIK3CA mutation (n = 21), followed by PTEN mutation (n = 12) and high tumor mutation burden (TMB-H) (n = 11). TMB-H was detected in 5 patients with cervical cancer, 5 with endometrial cancer, and 1 with endometrial stromal sarcoma. Eleven patients (10.8%) received molecularly targeted therapy according to their gene aberrations. Gene panel testing was mostly performed when the second-line treatment was ineffective. Of all 102 patients, 60 did not have recommended treatment, and 15 died or had worsened conditions before obtaining the test results. Conclusion: Through multigene panel testing, although many patients had druggable gene alterations, 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors. Furthermore, patients’ prognosis and performance status should be considered before performing the test.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 誌上ディベート　子宮頸部高度異形成(CIN3)に対して円錐切除vs.レーザー照射(非切除)　円錐切除

    岩田 卓

    アンチ・エイジング医学 ((株)メディカルレビュー社)  19 ( 2 ) 156 - 159 2023.04

    ISSN  1880-1579

  • 子宮頸癌に対する放射線治療後腟狭窄に対してヘガールを用いた腟拡張療法を施行しQOLの改善を得た4例の後方視的検討

    椎名 美季, 横田 めぐみ, 大野 あゆみ, 谷本 慧子, 千代田 達幸, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    日本女性医学学会雑誌 ((一社)日本女性医学学会)  30 ( 1 ) 94 - 94 2022.10

    ISSN  2185-8861

  • HPV検査を含んだ子宮頸がん検診アルゴリズムについて　細胞診陰性/HPV陽性の管理　Evidenceに基づく細胞診陰性HPV陽性症例の取り扱い

    西尾 浩, 岩田 卓, 青木 大輔

    日本臨床細胞学会雑誌 ((公社)日本臨床細胞学会)  61 ( Suppl.2 ) 400 - 400 2022.10

    ISSN  0387-1193

  • 子宮頸部病変のフォローアップにおけるLC-1000ランク分類の臨床的有用性の検討

    仲村 勝, 西尾 浩, 岩田 卓, 青木 大輔

    日本臨床細胞学会雑誌 ((公社)日本臨床細胞学会)  61 ( Suppl.2 ) 560 - 560 2022.10

    ISSN  0387-1193

  • 慢性骨盤痛患者に対する多診療科による対応について

    大野 あゆみ, 横田 めぐみ, 椎名 美季, 谷本 慧子, 吉浜 智子, 西尾 浩, 山上 亘, 弟子丸 亮太, 岩田 卓, 青木 大輔

    日本女性医学学会雑誌 ((一社)日本女性医学学会)  30 ( 1 ) 103 - 103 2022.10

    ISSN  2185-8861

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • がんサバイバーの健康管理

    岩田卓

    第38回日本女性医学学会学術集会 (徳島) , 

    2023.12
    , 

    Oral presentation (invited, special)

  • 授乳や乳製品摂取状況が超音波骨密度測定装置で測定した分娩前や産褥期骨密度に与える影響に関する検討

    荘 慎太郎, 春日 義史, 田中 邦生, 玉井 順子, 福間 優花, 大谷 利光, 池ノ上 学, 大橋 夕樹, 横田 めぐみ, 岩田 卓, 山上 亘, 田中 守

    第38回日本女性医学学会学術集会 (徳島) , 

    2023.12

  • ホルモン補充療法中に発生した子宮内膜癌の臨床的検討

    高畑 海音子, 横田 めぐみ, 仁木 晃子, 平松 真生子, 椎名 美季, 大野 あゆみ, 谷本 慧子, 坂井 健良, 西尾 浩, 岩田 卓, 弟子丸 亮太, 田中 守, 山上 亘

    第38回日本女性医学学会学術集会 (徳島) , 

    2023.12

  • 子宮頸部胃型粘液性癌における治療前の細胞診および組織診

    松田 理沙, 西尾 浩, 川井田 みほ, 岩田 卓, 松井 友哉, 横田 めぐみ, 大野 あゆみ, 大喜多 肇, 山上 亘

    第62回日本臨床細胞学会秋期大会 (福岡) , 

    2023.11

  • 進行期乳房外パジェット病の予後に関する単施設後方視的研究

    舩越 建, 中村 善雄, 平井 郁子, 小林 研太, 福田 桂太郎, 岩田 卓

    第61回日本癌治療学会学術集会 (横浜) , 

    2023.10

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 腫瘍浸潤リンパ球輸注療法（TIL療法）を実施した子宮頸癌患者の免疫応答解析

    2022.04
    -
    2025.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 基盤研究(B), Principal investigator

  • Development of TIL culture method for tumor infiltrating T cell therapy for cervical cancer

    2019.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • Analysis of molecular biological and tumor immunological characteristics of HPV negative cervical adenocarcinoma

    2015.04
    -
    2018.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PATHOPHYSIOLOGICAL ISSUES IN ACUTE CARE

    2024

  • MEDICAL PROFESSIONALISM 6

    2024

  • LECTURE SERIES, GYNECOLOGY

    2024

  • MEDICAL PROFESSIONALISM 6

    2023

  • LECTURE SERIES, GYNECOLOGY

    2023

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本免疫学会

    　

  • 日本産婦人科学会

    　

  • 日本癌学会

    　

  • 日本癌治療学会

    　

  • 日本臨床細胞学会

    　

display all >>

Page Top ▲